Our approach of directly targeting nutrient receptors in the gut through orally delivered molecules holds transformational potential to improve human health. We are currently advancing a diverse portfolio of novel, oral small-molecule therapies across three areas: metabolism, neurological disorders and gastrointestinal (GI) disease.
Therapeutic Areas of Focus
We are developing a number of novel, oral programs for the treatment of obesity, type 2 diabetes, and other diseases related to appetite and food intake that have significant
We have made significant advances using our proprietary Human Genetics Platform to identify multiple targets for neurological disorders, including migraine. We continue to focus our research efforts on therapeutic areas of high unmet need.
We are developing proprietary, orally-delivered, gut-targeted small molecules with a multi-targeted approach that focuses on novel, orthogonal mechanisms to current standards of care for gastrointestinal disease. These programs seek to restore gut epithelial cell homeostasis through activation of adenosine monophosphate-activated protein kinase (AMPK), dampening immune cell activation and inflammation in the GI mucosa through activation of AMPK and Tuft cell, and improving the secretory component of the GI barrier through Paneth cell and Tuft cell activation.